CERTIVOS VERIFIED
Janoshik Analytical
Independent Analysis
- Purity
- 99.89%
- Tested
- 2026-06-29
WNJKQXNY49QE
Currently Unavailable
Enter your email to be notified when this product is available.
For in vitro laboratory research use only. Not for human consumption. All products are supplied strictly for in vitro laboratory research use only. Not drugs, foods, supplements, or cosmetics. Not evaluated by Health Canada or the FDA.
Dose per Vial
40mg
Sold As
Single vial
Form
Lyophilized powder
Storage
2–8°C
Price
$205 CAD
Triple agonist (GIP/GLP-1/glucagon). 40mg lyophilized powder per vial.
VERIFICATION — Batch 2026-06-20
All compounds independently tested and verifiedLab results →
Research
Retatrutide
What It Is
Retatrutide is the triple threat — it hits GIP, GLP-1, AND glucagon receptors all at once. It's the first triple agonist to reach large clinical trials. The glucagon piece is the game-changer: it ramps up your body's energy expenditure and forces your liver to burn more fat. Early trial data produced the highest weight loss numbers ever seen in a controlled study.
How It Works
Three receptors, three effects. GLP-1 kills your appetite and slows digestion. GIP improves fat cell metabolism and insulin handling. Glucagon — the new addition — tells your liver to burn fat for fuel and cranks up thermogenesis (heat production = calories burned). The glucagon component is why retatrutide may cause more weight loss than even tirzepatide — it literally increases how many calories you burn at rest.
What The Research Shows
01
Phase 2 data showed up to 24.2% weight loss at 48 weeks at the highest dose — the most ever recorded in a controlled obesity trial at publication.
02
Up to 86% of participants normalized their liver fat levels. That's an extraordinary result for fatty liver.
03
Currently in Phase 3 trials (TRIUMPH program). If results hold, this becomes the most potent weight loss compound available.
04
Side effects are similar to other GLP-1 drugs — mostly GI (nausea, diarrhea), worst in the first weeks, improving with dose titration.
Sources
Triple-Hormone-Receptor Agonist Retatrutide for Obesity
Jastreboff AM et al. — N Engl J Med, 2023 · PubMed
Information derived from published preclinical and clinical research. Provided for educational purposes only — not medical advice.
Customer Reviews
- Ryan K.★★★★★
Customer service is top notch and fast delivery!
- Jamie★★★★★
Had my order confirmation instantly, shipping information within hours and product delivered in 2 business days.
- Jessica T.★★★★★
Great communication when a product came back in stock and even got a free bottle of bac water!
- Sanjiv R.★★★★★
Product quality is the best and had it delivered to my office within 72 hours of ordering.